Cytiva will also look to grow through expanded activity in cell and gene therapies—and additional work with customers working toward COVID-19 drugs, vaccines, and tests . . .
The post Cytiva Picks Up Where GE Leaves Off after $21B Deal appeared first on GEN – Genetic Engineering and Biotechnology News.
